GlassScriptPhysician profile
Valerie J Dye
NPI 1821009663
$4,850.61
in general payments reported to CMS, 2019-2025
28 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $152 · 2021: $1,350 · 2022: $412 · 2023: $336 · 2024: $1,013 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.05 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $846.33 | 2019-2023 | Veltassa, Korsuva |
| Amgen INC. | $812.61 | 2019-2024 | Parsabiv, Tavneos, Krystexxa |
| Ardelyx, INC. | $488.99 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $413.77 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $240.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $233.19 | 2019-2023 | Farxiga |
| Akebia Therapeutics INC | $212.73 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $187.66 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $161.76 | 2019-2025 | Ultomiris |
| Ani Pharmaceuticals, INC. | $154.51 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $150.25 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.24 | 2023-2024 | Jardiance |
| Fresenius USA Marketing, INC. | $137.20 | 2019-2024 | Velphoro |
| Aurinia Pharma U.S., INC. | $106.76 | 2021-2024 | Lupkynis |
| Lilly USA, LLC | $97.09 | 2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $90.62 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.45 | 2021-2023 | Gattex |
| Glaxosmithkline, LLC. | $53.00 | 2022-2025 | Shingrix, Benlysta |
| Mallinckrodt Enterprises LLC | $50.82 | 2019 | |
| Bard Peripheral Vascular, INC. | $39.86 | 2020-2023 | Pristine |
| Apellis Pharmaceuticals, INC. | $34.95 | 2025 | Empaveli |
| Calliditas Therapeutics US INC. | $33.41 | 2025 | Tarpeyo |
| Cormedix INC. | $20.99 | 2024 | Defencath |
| Alnylam Pharmaceuticals INC. | $19.26 | 2025 | Onpattro |
| Opko Pharmaceuticals, LLC | $18.98 | 2021 | |
| Novo Nordisk INC | $15.32 | 2024 | Wegovy |
| Ultragenyx Pharmaceutical INC. | $15.01 | 2025 | Crysvita |
| Genzyme Corporation | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valerie Dye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.